Jun 24, 2020 9:33 pm EDT Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock
Jun 22, 2020 4:33 pm EDT Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock
May 22, 2020 7:00 am EDT Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020
May 19, 2020 7:00 am EDT New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions
May 5, 2020 7:00 am EDT Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma
Apr 29, 2020 7:00 am EDT Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma
Apr 27, 2020 7:00 am EDT Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020
Apr 6, 2020 7:00 am EDT Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
